Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Molecular Biology ReportsOpen Access

Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

FAFatemeh AhangariMAMina AlimohammadiSHSeyed Mahmoud Hashemi

Discussion

Loading...

Member takes

Overview

Therapy using mesenchymal stromal cell-derived extracellular vesicles shows potential for reducing inflammatory cytokines in graft-versus-host disease, implying improved immunomodulation.

Key Points

  • Therapy with extracellular vesicles effectively alters inflammatory cytokine responses in graft-versus-host disease, targeting donor immune cells.
  • Significant findings highlight the potential role of mesenchymal stromal cells in enhancing the function of regulatory T-cells in immunopathology processes.
  • Hematopoietic cell transplantation shows limited efficacy without novel therapies like mesenchymal stromal cell-derived vesicles for better treatment outcomes.
  • Improved therapeutic strategies in graft-versus-host disease may hinge on advancements in immunomodulation via innovative cell therapy methods.

Cite This Study

Ahangari et al. (2025) studied this question.

synapsesocial.com/papers/6930dc92ea1aef094cca2b72https://doi.org/10.1007/s11033-025-11295-4
View Full Paper
Ask AI
Bookmark
Share